Overview

Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.
Phase:
Phase 2
Details
Lead Sponsor:
NovaCardia, Inc.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Rolofylline